超声分子成像引导超声触发脂质体阿霉素释放及其在大鼠原位前列腺肿瘤模型中的治疗监测
研究在大鼠原位前列腺肿瘤模型中,用靶向VEGFR2的超声造影剂BR55进行超声分子成像(USMI),引导聚焦超声触发声敏脂质体阿霉素(L-DXR)局部释放。USMI可精准引导触发释放,B模式联合USMI有助于随访肿瘤治疗反应。
要点
- USMI用靶向VEGFR2的BR55可精准定位肿瘤,引导聚焦超声触发脂质体药物局部释放。
- 联合超声触发释放较单用脂质体阿霉素显著增强肿瘤缩小效果(70% vs 20%,p<0.01)。
- B模式联合USMI可用于随访肿瘤对治疗的反应,触发释放前后灌注及VEGFR2表达未见差异。
关键影像表现/征象
- USMI使用靶向VEGFR2的BR55可显示肿瘤血管,为超声触发释放提供精准定位引导。
- B模式成像联合USMI可用于随访肿瘤对治疗的反应。
- 触发释放前后肿瘤灌注及VEGFR2表达未见差异(USMI与CD31、VEGFR2免疫组化评估)。
诊断标准与关键数值
- 单用L-DXR组2周肿瘤缩小20%(n=9),L-DXR联合共聚焦超声触发组缩小70%(n=7),差异p<0.01。
临床应用与阅片要点
- 阅片时可利用USMI(BR55靶向VEGFR2)定位肿瘤血管以规划超声触发释放区域。
- 随访中联合B模式与USMI评估肿瘤缩小及治疗反应,注意触发释放前后灌注和VEGFR2表达可能无明显变化。
局限性
- 研究为大鼠原位前列腺肿瘤模型,样本量有限(n=9和n=7),结论向临床转化需进一步验证。
- 原文未报告USMI引导触发释放的敏感度、特异度或AUC等诊断效能指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Liposome encapsulation of drugs is an interesting approach in cancer therapy to specifically release the encapsulated drug at the desired treatment site. In addition to thermo-, pH-, light-, enzyme- or redox-responsive liposomes, which have had promising results in (pre-) clinical studies, ultrasound-triggered sonosensitive liposomes represent an exciting alternative to locally trigger the release from these cargos. Localized drug release requires precise tumor visualization to produce a targeted and ultrasound stimulus. We used ultrasound molecular imaging (USMI) with BR55, a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasound contrast agent, to guide ultrasound-triggered release of sonosensitive liposomes encapsulating doxorubicin (L-DXR) in an orthotopic prostatic rodent tumor model. Forty-eight hours after L-DXR injection, local release of doxorubicin was triggered with a confocal ultrasound device with two focused transducers, 1.1-MHz center frequency, and peak positive and negative pressures of 20.5 and 13 MPa at focus. Tumor size decreased by 20% in 2 wk with L-DXR alone (n = 9) and by 70% after treatment with L-DXR and confocal ultrasound (n = 7) (p < 0.01). The effect of doxorubicin on perfusion/vascularity and VEGFR2 expression was evaluated by USMI and immunohistochemistry of CD31 and VEGFR2 and did not reveal differences in perfusion or VEGFR2 expression in the absence or after the triggered release of liposomes. USMI can provide precise guidance for ultrasound-triggered release of liposomal doxorubicin mediated by a confocal ultrasound device; moreover, the combination of B-mode imaging and USMI can help to follow the response of the tumor to the therapy.
引用
- Helbert A, von Wronski M, Mestas JL, et al. Ultrasound Molecular Imaging for the Guidance of Ultrasound-Triggered Release of Liposomal Doxorubicin and Its Treatment Monitoring in an Orthotopic Prostatic Tumor Model in Rat. Ultrasound Med Biol. 2021. PMID: 34503895. doi:10.1016/j.ultrasmedbio.2021.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。